We use cookies to ensure that we give you the best experience on your website. If you continue without changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use. For Medical questions regarding any BTG products, please contact medical.services@btgplc.com
* BTG IM are not responsible for Noteworthy News content
25 Aug 2016
BTG International Canada Inc. announced it received approval for its drug-eluding device, the DC Bead LUMI, from Health Canada. The bead is the first commercially available product for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.
6 May 2016
BTG Group is buying a US company that develops medical devices which kill tumours by freezing them, as it looks to further boost its presence in the world of interventional oncology.
12 Apr 2016
Treating cancer that began in the liver or has spread to the liver can often involve months of chemotherapy and painful radiation treatments. But now there’s a new procedure that takes tiny beads that carry a high dose of radiation and sends them straight to the cancer.
7 Jan 2016
PATIENT PERSPECTIVE When Eleanor Cook’s cancer spread to her liver, it was a sign that something in her treatment regimen had to change.
RESEARCH ADVANCES In October, iconic buildings throughout the United Kingdom were bathed in pink light. NFL players wore pink on their shoes during games across the U.S. and, in Canada, hundreds attended high-profile galas.